Arends Joop E, Lieveld Faydra I, Ahmad Shazaad, Ustianowski Andrew
Department of Internal Medicine, Section Infectious Diseases, University Medical Center Utrecht, Utrecht, The Netherlands.
Utrecht University, Utrecht, The Netherlands.
Infect Dis Ther. 2017 Dec;6(4):461-476. doi: 10.1007/s40121-017-0173-y. Epub 2017 Oct 25.
Although current therapies can be successful at suppressing hepatitis B viral load, long-term viral cure is not within reach. Subsequent strategies combining pegylated interferon alfa with nucleoside/nucleotide analogues have not resulted in any major paradigm shift. An improved understanding of the hepatitis B virus (HBV) lifec ycle and virus-induced immune dysregulation has, however, revealed many potential therapeutic targets, and there are hopes that treatment of hepatitis B could soon be revolutionized. This review summarizes the current developments in HBV therapeutics-both virus directed and host directed.
尽管目前的疗法能够成功抑制乙肝病毒载量，但长期的病毒治愈仍难以实现。随后将聚乙二醇化干扰素α与核苷/核苷酸类似物联合使用的策略并未带来任何重大的模式转变。然而，对乙肝病毒（HBV）生命周期以及病毒诱导的免疫失调的进一步了解揭示了许多潜在的治疗靶点，人们希望乙肝治疗很快能发生变革。本综述总结了HBV治疗学的当前进展，包括针对病毒和针对宿主的治疗进展。
